> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Glaxo sNDA for COPD
- URL: https://www.fdaweb.com/panel-to-discuss-glaxo-snda-for-copd/
- Published: 2020-08-10T12:00:00.000Z
- Updated: 2026-09-14T16:24:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147390

*Federal Register* notice: FDA announces an 8/31 online Pulmonary-Allergy Drugs Advisory Committee meeting. Panel members are scheduled to a discuss a GlaxoSmithKline supplemental NDA for Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder oral inhalation), indicated for reducing all-cause mortality in patients with chronic obstructive pulmonary disease. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-17533.pdf?ref=fdaweb.com).